Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

asclemed usa, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

proficient rx lp - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Kanada - engleski - Health Canada

odan laboratories ltd - sulfacetamide sodium - solution - 10% - sulfacetamide sodium 10% - antibacterials

Kanada - engleski - Health Canada

allergan inc - sulfacetamide sodium; prednisolone acetate - ointment - 10%; 0.2% - sulfacetamide sodium 10%; prednisolone acetate 0.2% - sulfonamides

Kanada - engleski - Health Canada

odan laboratories ltd - sulfacetamide sodium; prednisolone acetate - solution - 100mg; 5mg - sulfacetamide sodium 100mg; prednisolone acetate 5mg - sulfonamides

Kanada - engleski - Health Canada

allergan inc - sulfacetamide sodium; prednisolone acetate - drops - 10%; 0.2% - sulfacetamide sodium 10%; prednisolone acetate 0.2% - sulfonamides

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed. information for patients: patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. the use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. avoid contact with eyes, lips and mucous membranes. drug interactions: this product is incompatible with silver preparations. carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on this product to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown. pregnancy: category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. this product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. nursing mothers: it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman. pediatric use: safety and effectiveness in children under the age of 12 years have not been established.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

medimetriks pharmaceuticals, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - sumaxin® (sodium sulfacetamide 10% & sulfur 4%) cleansing pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sumaxin® (sodium sulfacetamide 10% & sulfur 4%) cleansing pads are contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sumaxin® (sodium sulfacetamide 10% & sulfur 4%) cleansing pads are not to be used by patients with kidney disease.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

exact-rx, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - indications : sodium sulfacetemide 10% wash is intended for topical application in the following scaling dermatoses: seborrheic dermatisis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. contraindications: sodium sulfacetamide 10% wash is contraindicated in persons with know or suspected hypersensitivity to sulfonamides.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

exact-rx, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - indications : sodium sulfacetemide 10% and sulfer 5% cleanser is indicated for he topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications : sodium sulfacetamide 10% & sulfer 5% cleanser is contraindicated in persons with know or suspected hypersensitivity to sulfonamides, sulfer or any other component of this preparation. sodium sulfacetamide 10% & sulfer %5% cleanser is not to be used by patients with kidney disease. caution : if redness or irritaiton occurs, discontinue use.